Review supports post-PCI use of dual antiplatelet therapy

07/10/2013 | Healio

A data review found dual antiplatelet therapy is the mainstay treatment for reducing cardiovascular risks after percutaneous coronary intervention, according to researchers from the University of Texas Southwestern Medical Center. The study, published in the Journal of the American Medical Association, recommended the low-dose aspirin component be continued indefinitely and a P2Y12 inhibitor should be prescribed for 12 months, unless patients are at high risk for bleeding.

View Full Article in:

Healio

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ
Chief Executive Officer
UCare Minnesota
Minneapolis, MN
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC